Trump’s 'Most Favored Nation' Policy: Vows To Slash U.S. Drug Prices By Up to 80% In Bold New Plan

In a bold move announced on Truth Social, US President Donald Trump has committed to drastically lowering the cost of prescription drugs and pharmaceuticals in the United States, with reductions potentially reaching up to 80%. This initiative, which is set to be formalized through an executive order, marks a significant resurgence of a pivotal agenda from Trump's earlier tenure. The plan aims to provide Americans with immediate financial relief from the burdensome prices of medications, addressing a longstanding issue that has seen US drug prices soar above those in other nations.

Trump’s strategy involves the implementation of a "MOST FAVORED NATION'S POLICY," which would align the prices of drugs in the US with the lowest prices paid by any other country for the same products. This approach is expected to bring about unprecedented reductions in healthcare costs for US citizens, with Trump asserting that the country will, at last, receive fair treatment. The president criticized pharmaceutical companies for charging exorbitant prices under the guise of covering research and development costs, a practice he vows to end, emphasizing that such tactics will not influence his administration or the Republican Party.

Trump highlighted the injustice of the current pricing model, where drugs are often priced several times higher in the US than in other countries, despite being produced in the same facilities by the same companies. He questioned the rationale behind such disparities, pointing to the urgent need for reform. The anticipated policy changes are not only aimed at significantly lowering drug prices in the US by 30 to 80 percent but also at adjusting prices globally to ensure fairness. Trump argues that this realignment is necessary for equitable drug pricing, promising that the shift will bring fairness back to America.

The focus of Trump's executive order would be on medications administered in healthcare settings and covered by Medicare Part B, including costly treatments like cancer therapies and injectable drugs. These medications, which accounted for $33 billion in expenses in 2021, represent some of the highest costs borne by Medicare. Trump's insistence on the policy's potential to "save TRILLIONS OF DOLLARS" underscores his determination to alter the landscape of drug pricing, despite expecting strong opposition from pharmaceutical companies. Despite a similar proposal being thwarted in court during Trump’s first term—due to heavy lobbying by the pharmaceutical industry, which argued that such price controls would stifle innovation and allow foreign pricing to dictate US drug costs—Trump remains optimistic.

He asserts that the outcome will be different this time, aiming to overcome resistance and enact significant healthcare cost reductions. This initiative reiterates Trump's commitment to tackling high medication costs, a critical issue from his initial presidential campaign. At the TOI World Desk, our team of experienced journalists and passionate writers is dedicated to delivering timely, accurate, and in-depth news from around the globe. We endeavor to provide our readers with a comprehensive understanding of world events, offering diverse perspectives on the stories that connect us all. Join us as we explore the complexities of our global community, keeping you informed every step of the way.